Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease

Braak, 2003, Staging of brain pathology related to sporadic Parkinson’s disease, Neurobiol. Aging, 24, 197, 10.1016/S0197-4580(02)00065-9 Abou-Sleiman, 2006, Expanding insights of mitochondrial dysfunction in Parkinson’s disease, Nat. Rev. Neurosci., 7, 207, 10.1038/nrn1868 Hashimoto, 2003, Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases, Neuromolecular Med., 4, 21, 10.1385/NMM:4:1-2:21 Youdim, 1993, The role of iron in senescence of dopaminergic neurons in Parkinson’s disease, J Neural Transm. Suppl., 40, 57 Conway, 2001, Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct, Science, 294, 1346, 10.1126/science.1063522 Halliwel, 1989, Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson’s disease, Alzheimer’s disease, traumatic injury or stroke?, Acta Neurol. Scand. Suppl., 126, 23, 10.1111/j.1600-0404.1989.tb01779.x Hashimoto, 1999, Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro, Neuroreport, 10, 717, 10.1097/00001756-199903170-00011 Dawson, 2003, Molecular pathways of neurodegeneration in Parkinson’s disease, Science, 302, 819, 10.1126/science.1087753 Hattori, 2004, Pathogenetic mechanisms of parkin in Parkinson’s disease, Lancet, 364, 722, 10.1016/S0140-6736(04)16901-8 Taira, 2001, Molecular cloning of human and mouse DJ-1 genes and identification of Sp1-dependent activation of the human DJ-1 promoter, Gene, 263, 285, 10.1016/S0378-1119(00)00590-4 Bonifati, 2004, Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson’s disease, J. Mol. Med., 82, 163, 10.1007/s00109-003-0512-1 Annesi, 2005, DJ-1 mutations and parkinsonism–dementia–amyotrophic lateral sclerosis complex, Ann. Neurol., 58, 803, 10.1002/ana.20666 Calne, 1992, Criteria for diagnosing Parkinson’s disease, Ann. Neurol., 32, S125, 10.1002/ana.410320721 Hoehn, 1967, Parkinsonism: onset, progression and mortality, Neurology, 17, 427, 10.1212/WNL.17.5.427 Hashimoto, 1998, Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease, Brain Res., 799, 301, 10.1016/S0006-8993(98)00514-9 Baulac, 2004, Dimerization of Parkinson’s disease-causing DJ-1 and formation of high molecular weight complexes in human brain, Mol. Cell. Neurosci., 27, 236, 10.1016/j.mcn.2004.06.014 Zhou, 2005, DJ-1 upregulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity, J. Biol. Chem., 280, 43150, 10.1074/jbc.M507124200 Kim, 2005, Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress, Proc. Natl. Acad. Sci. USA, 102, 5215, 10.1073/pnas.0501282102 Menzies, 2005, Roles of Drosophila DJ-1 in survival of dopaminergic neurons and oxidative stress, Curr. Biol., 15, 1578, 10.1016/j.cub.2005.07.036 Meulener, 2005, Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson’s disease, Curr. Biol., 15, 1572, 10.1016/j.cub.2005.07.064 Yang, 2005, Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling, Proc. Natl. Acad. Sci. USA, 102, 13670, 10.1073/pnas.0504610102 Mitsumoto, 2001, DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin, Free Radic. Res., 35, 885, 10.1080/10715760100301381 Ito, 2006, Roles of distinct cysteine residues in S-nitrosylation and dimerization of DJ-1, Biochem. Biophys. Res. Commun., 339, 667, 10.1016/j.bbrc.2005.11.058 Kim, 2005, DJ-1, a novel regulator of the tumor suppressor PTEN, Cancer Cell, 7, 263, 10.1016/j.ccr.2005.02.010 Neumann, 2004, Pathological properties of the Parkinson’s disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick’s disease, Acta Neuropathol. (Berl), 107, 489, 10.1007/s00401-004-0834-2 Choi, 2006, Oxidative damage of DJ-1 is linked to sporadic Parkinson’s and Alzheimer’s diseases, J. Biol. Chem., 281, 10816, 10.1074/jbc.M509079200 Bandopadhyay, 2004, The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson’s disease, Brain, 127, 420, 10.1093/brain/awh054 Bader, 2005, Expression of DJ-1 in the adult mouse CNS, Brain Res., 1041, 102, 10.1016/j.brainres.2005.02.006 Allard, 2005, PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke, Clin. Chem., 51, 2043, 10.1373/clinchem.2005.053942 Green, 2002, Cerebrospinal fluid brain-derived proteins in the diagnosis of Alzheimer’s disease and Creutzfeldt–Jakob disease, Neuropathol. Appl. Neurobiol., 28, 427, 10.1046/j.1365-2990.2002.t01-2-00427.x Van Everbroeck, 2005, Cerebrospinal fluid biomarkers in Creutzfeldt–Jakob disease, Clin. Neurol. Neurosurg., 107, 355, 10.1016/j.clineuro.2004.12.002 Grossman, 2005, Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease, Ann. Neurol., 57, 57721, 10.1002/ana.20477 Jakowec, 1998, The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with Parkinson’s disease or normal controls, Neurosci. Lett., 253, 13, 10.1016/S0304-3940(98)00599-0 Borghi, 2000, Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson’s disease and normal subjects, Neurosci. Lett., 287, 65, 10.1016/S0304-3940(00)01153-8 El-Agnaf, 2006, Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease, FASEB J., 20, 419, 10.1096/fj.03-1449com